Response to mRNA SARS‐CoV ‐2 vaccination evaluated by B‐cell receptor repertoire after tixagevimab/cilgavimab administration
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18932 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Yohei Funakoshi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: COVID-19, Hematologic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
The use of anti‐SARS‐CoV‐2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID‐19. Although patients who receive these agents should still be vaccinated, the use of tixagevimab/cilgavimab can mask the production of anti‐spike antibody after vaccination, making it hard to assess vaccine response. We have newly established a quantification method to assess the response to SARS‐CoV‐2 vaccination at the mRNA level using B‐cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV‐AbDab). Repeated blood samples before and after vaccination were analysed for the BCR repertoire, and BCR sequences were searched in the database. We analysed the number and percentage frequency of matched sequences. We found that the number of matched sequences increased 2 weeks after the first vaccination and quickly decreased. Meanwhile, the number of matched sequences more rapidly increased after the second vaccination. These results show that the postvaccine immune response can be assessed at the mRNA level by analysing the fluctuation in matching sequences. Finally, BCR repertoire analysis with CoV‐AbDab clearly demonstrated the response to mRNA SARS‐CoV‐2 vaccination even after tixagevimab/cilgavimab administration in haematological malignancy patients who underwent allogeneic haematopoietic stem cell transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
- Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
- Research & Development Department, Repertoire Genesis Inc., Ibaraki, Japan.
- R&D, Cellspect Co., Ltd., Morioka, Japan.
- Division of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, Kobe, Japan.
- Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, Kobe, Japan.
ORCID-Profile: Yohei Funakoshi, Kimikazu Yakushijin
Zitieren
APA
Funakoshi, Y., Yakushijin, K., Ohji, G., Matsutani, T., Hojo, W., Sakai, H., Matsumoto, S., Watanabe, M., Kitao, A., Saito, Y., Kawamoto, S., Yamamoto, K., Koyama, T., Nagatani, Y., Kimbara, S., Imamura, Y., Kiyota, N., Ito, M., & Minami, H. (2023). Response to mRNA SARS‐CoV ‐2 vaccination evaluated by B‐cell receptor repertoire after tixagevimab/cilgavimab administration. British Journal of Haematology. https://doi.org/10.1111/bjh.18932
Vancouver
Funakoshi Y, Yakushijin K, Ohji G, Matsutani T, Hojo W, Sakai H, et al. Response to mRNA SARS‐CoV ‐2 vaccination evaluated by B‐cell receptor repertoire after tixagevimab/cilgavimab administration. British Journal of Haematology. 2023. doi:10.1111/bjh.18932
BibTeX
@article{Funakoshi2023,
author = {Funakoshi, Yohei and Yakushijin, Kimikazu and Ohji, Goh and Matsutani, Takaji and Hojo, Wataru and Sakai, Hironori and Matsumoto, Sakuya and Watanabe, Marika and Kitao, Akihito and Saito, Yasuyuki and Kawamoto, Shinichiro and Yamamoto, Katsuya and Koyama, Taiji and Nagatani, Yoshiaki and Kimbara, Shiro and Imamura, Yoshinori and Kiyota, Naomi and Ito, Mitsuhiro and Minami, Hironobu},
title = {Response to mRNA SARS‐CoV ‐2 vaccination evaluated by B‐cell receptor repertoire after tixagevimab/cilgavimab administration},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18932}
}
EUVIMED